Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received the mRNA-1273 primary series (100-µg) and mRNA-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R., Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne E., Chen, Xing, Ying Chang, Sutherland, Andrea, Montefiori, David C., Girard, Bethany, Edwards, Darin K., Jing Feng, Zhou, Honghong, Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447540/
https://www.ncbi.nlm.nih.gov/pubmed/37612300
http://dx.doi.org/10.1038/s41467-023-38892-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447540/
https://www.ncbi.nlm.nih.gov/pubmed/37612300
http://dx.doi.org/10.1038/s41467-023-38892-w

Ejemplares similares